CRISPR Therapeutics AG (CRSP)는 중증 질환을 위한 유전자 기반 의약품을 개척하는 데 헌신하는 생명공학 기업이다. 회사는 독점적인 Clustered Regularly Interspaced Short Palindromic ...
Sumitomo Mitsui Trust Group Inc.는 2026년 1분기 CRISPR Therapeutics AG($CRSP) 지분을 5.3% 줄여 104,000주 이상을 매각하고 185만 주를 보유하게 됐다. 해당 지분은 약 8,820만 달러 규모다. 이러한 감축에도 불구하고 회사가 Q1 EPS -$1.28과 낮은 매출을 보고하는 등 부진한 가운데서도, 애널리스트들의 평가는 "보통 매수(Moderate Buy)" 컨센서스 등급과 평균 목표주가 67.78달러로 여전히 신중하게 긍정적이다. 기관 투자자들은 회사 주식의 69.20%를 공동으로 보유하고 있다.
CRISPR Therapeutics AG(CRSP)는 광범위한 시장이 상승하는 가운데 주가가 5.31% 하락했다. 최근 조정에도 불구하고 회사 주가는 지난 한 달 동안 12.16% 상승해, 해당 업종과 S&P 500을 능가했다. 애널리스트들은 CRSP의 예정된 실적 발표에서 이익과 매출 모두 전년 대비 큰 성장을 예상하고 있으며, 회사는 현재 재크스(Zacks) 레이팅 3위(#3, Hold: 보유)를 받고 있다.
뱅크 오브 아메리카 증권 애널리스트 앨릭 스트라나한(Alec Stranahan)은 Crispr Therapeutics AG(CRSP)에 대해 83달러 목표주가와 함께 매수(Buy) 등급을 재확인했다. 이는 파이퍼 샌들러(Piper Sandler)가 제시한 유사한 매수 등급에 따른 것이다. 회사는 최신 실적 발표에서 분기 매출 146만 달러와 GAAP 기준 순손실 1억 2,293만 달러를 보고했다.
뱅크 오브 아메리카 증권은 Crispr Therapeutics AG(CRSP)에 대해 83.00달러 목표주가로 매수(Buy) 등급을 유지했다. 이는 파이퍼 샌들러가 110.00달러 목표주가로 유사하게 재확인한 것에 따른 것이다. 회사는 1분기 매출 146만 달러와 GAAP 기준 순손실 1억 2,293만 달러를 보고했으며, 이는 전년 대비 개선된 수치다.
이 기사는 유전자 편집과 체중 감량에 서로 다른 초점을 가진 두 생명공학 기업인 CRISPR 테라퓨틱스와 바이킹 테라퓨틱스를 비교합니다. CRISPR 테라퓨틱스는 이미 유전자 치료제 Casgevy를 출시한 반면, 바이킹 테라퓨틱스는 현재 매출이 없는 임상 단계 기업이지만 파이프라인에서 가능성 있는 약물을 보유하고 있습니다. 분석에 따르면 두 회사 모두 성장 잠재력이 큰 시장에서 활동하고 있음에도, CRISPR 테라퓨틱스는 사업화 성과를 바탕으로 2026년에 더 나은 선택으로 제시됩니다.
Sumitomo Mitsui Trust Group Inc.는 2026년 1분기 CRISPR Therapeutics AG($CRSP) 지분을 5.3% 줄여 104,000주 이상을 매각하고 185만 주를 보유하게 됐다. 해당 지분은 약 8,820만 달러 규모다. 이러한 감축에도 불구하고 회사가 Q1 EPS -$1.28과 낮은 매출을 보고하는 등 부진한 가운데서도, 애널리스트들의 평가는 "보통 매수(Moderate Buy)" 컨센서스 등급과 평균 목표주가 67.78달러로 여전히 신중하게 긍정적이다. 기관 투자자들은 회사 주식의 69.20%를 공동으로 보유하고 있다.
CRISPR Therapeutics AG(CRSP)는 광범위한 시장이 상승하는 가운데 주가가 5.31% 하락했다. 최근 조정에도 불구하고 회사 주가는 지난 한 달 동안 12.16% 상승해, 해당 업종과 S&P 500을 능가했다. 애널리스트들은 CRSP의 예정된 실적 발표에서 이익과 매출 모두 전년 대비 큰 성장을 예상하고 있으며, 회사는 현재 재크스(Zacks) 레이팅 3위(#3, Hold: 보유)를 받고 있다.
뱅크 오브 아메리카 증권 애널리스트 앨릭 스트라나한(Alec Stranahan)은 Crispr Therapeutics AG(CRSP)에 대해 83달러 목표주가와 함께 매수(Buy) 등급을 재확인했다. 이는 파이퍼 샌들러(Piper Sandler)가 제시한 유사한 매수 등급에 따른 것이다. 회사는 최신 실적 발표에서 분기 매출 146만 달러와 GAAP 기준 순손실 1억 2,293만 달러를 보고했다.
뱅크 오브 아메리카 증권은 Crispr Therapeutics AG(CRSP)에 대해 83.00달러 목표주가로 매수(Buy) 등급을 유지했다. 이는 파이퍼 샌들러가 110.00달러 목표주가로 유사하게 재확인한 것에 따른 것이다. 회사는 1분기 매출 146만 달러와 GAAP 기준 순손실 1억 2,293만 달러를 보고했으며, 이는 전년 대비 개선된 수치다.
이 기사는 유전자 편집과 체중 감량에 서로 다른 초점을 가진 두 생명공학 기업인 CRISPR 테라퓨틱스와 바이킹 테라퓨틱스를 비교합니다. CRISPR 테라퓨틱스는 이미 유전자 치료제 Casgevy를 출시한 반면, 바이킹 테라퓨틱스는 현재 매출이 없는 임상 단계 기업이지만 파이프라인에서 가능성 있는 약물을 보유하고 있습니다. 분석에 따르면 두 회사 모두 성장 잠재력이 큰 시장에서 활동하고 있음에도, CRISPR 테라퓨틱스는 사업화 성과를 바탕으로 2026년에 더 나은 선택으로 제시됩니다.
이 기사는 2026년의 잠재적 투자 기회로서 CRISPR 테라퓨틱스와 바이킹 테라퓨틱스를 비교하며 위험 프로필, 사업화 단계, 재무 밸류에이션을 종합적으로 평가합니다. Casgevy를 성공적으로 출시한 CRISPR 테라퓨틱스는 유전자 편집에 집중하는 반면, 바이킹 테라퓨틱스는 고성장 비만 약물 시장을 겨냥하는 임상 단계 기업입니다. 분석에 따르면 바이킹이 진입하려는 경쟁이 치열한 GLP-1 시장에도 불구하고, CRISPR 테라퓨틱스는 확립된 제품과 시장 진입을 바탕으로 더 나은 투자처로 제시됩니다.
이 기사는 CRISPR Therapeutics AG(CRSP)에 대한 상세한 재무 및 주식 옵션 데이터를 제공합니다. 시가총액, 수익, 매출, EPS, 다양한 성과 지표, 내부자/기관 소유 비율과 함께 최근 거래 성과 및 애널리스트 추천 사항 등을 포함합니다.
Citizens는 CRISPR Therapeutics(NASDAQ:CRSP) 주식에 대해 Market Outperform 등급과 목표주가 80.00달러를 유지했으며, 회사 주가는 현재 60.08달러에 거래되고 있고 지난주 6.6% 상승했다고 밝혔습니다. 이 회사는 CASGEVY 라벨이 2세 이상 환자에게까지 확대되면 총잠재시장(TAM)을 크게 늘릴 수 있다고 보고 있습니다. Citizens는 또한 Beam Therapeutics의 risto-cel처럼 CASGEVY를 대체할 수 있는 경쟁 치료제에서 오는 제한적인 위험을 보며, 수혈 센터 내에서 CASGEVY가 이미 확립된 통합을 갖추고 있다고 강조했습니다.
CRISPR Therapeutics (CRSP) was recently added to several Russell growth indexes, increasing its visibility to growth-focused investors and potentially influencing its investment narrative. While this inclusion may boost liquidity and market reactions, it doesn't fundamentally alter the core investment case, which still depends on clinical milestones, regulatory progress, and managing cash burn. Investors are cautioned to consider the wide dispersion in fair value estimates and the company's ongoing losses and funding risks.
CRISPR Therapeutics (CRSP) stock has experienced a significant breakout from a multi-week consolidation, confirmed by strong trading volume. This breakout from dual inverse head and shoulders patterns suggests a bullish reversal and potential for higher prices, with measured targets indicating upside towards $68-$81. The analysis points to the February high of $61.76 as the next key resistance, a decisive breach of which would further confirm the reversal of the intermediate downtrend.
The article discusses why CRISPR Therapeutics AG (CRSP) is a heavily searched stock, focusing on its earnings estimates, revenue growth, and valuation. CRSP has outperformed the S&P 500 and its industry recently, but its Zacks Rank is a #3 (Hold) due to recent estimate changes and other factors. The company shows strong projected revenue growth but has a "F" grade on Zacks Value Style Score, suggesting it may be trading at a premium.
This article lists various Exchange Traded Funds (ETFs) that hold shares of CRISPR Therapeutics AG (0VRQ). The list, sorted by market value, provides details such as the percentage weight of CRISPR in the ETF, the issuer, management style, focus, expense ratio, assets under management (AUM), price, and 3-year NAV total return. These ETFs offer investors a diversified way to gain exposure to CRISPR Therapeutics AG with potentially lower risk.
CRISPR Therapeutics AG (NasdaqGM:CRSP), a gene-editing company, has been added to the Russell 2000 Growth Benchmark. The company's stock is currently trading at $56.35, with a positive year-to-date change. This inclusion is among several recent additions to various Russell benchmarks.
CRISPR Therapeutics AG (NasdaqGM: CRSP) has been added to the Russell 3000E Growth Benchmark. The company, a Switzerland-based gene editing firm, focuses on developing CRISPR/Cas9-based therapeutics to treat genetically defined diseases and engineer advanced cellular therapies. This inclusion highlights its growth prospects and strategic position in the biotechnology sector.
Analysts have recently raised revenue and EPS forecasts for CRISPR Therapeutics, suggesting increased confidence in the company's near-term gene-editing revenue potential, partly due to its partnership with Vertex. While this optimism could sharpen near-term catalysts, investors should remain mindful of the company's reliance on external funding and ongoing unprofitability. Despite potential undervaluation, diverse fair value estimates reflect varying long-term expectations for the gene-editing firm.
This article provides the "Price to sales forward" metric for CRISPR Therapeutics AG (DUS:1CG). The financial data is sourced from ICE Data Services and FactSet Research Systems Inc., with SEC filings provided by Quartr. The specific value for this metric is not detailed in the provided text.
This article provides a brief overview of CRISPR Therapeutics AG (NASDAQ: CRSP) focusing on its price to sales forward metric. It also lists various financial and community features available on the TradingView platform for this stock. The content indicates that the market is currently closed with no trades.
This article provides financial data specifically regarding the Enterprise Value to EBIT forward ratio for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication and presents a table showing the period, value, change, and percentage change for this financial metric.
This article headline indicates a financial analysis for CRISPR Therapeutics AG (NASDAQ:CRSP), specifically focusing on its enterprise value to forward revenue ratio. The content appears to be a stub or an indication of where such financial data would be presented on the TradingView platform.
This article provides the enterprise value to EBITDA forward for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication with no trades, and offers various financial and community data points related to the company.
This article displays the "Enterprise value to EBIT forward" for CRISPR Therapeutics AG, listed under the stock symbol DUS:1CG on the Dusseldorf Stock Exchange. It indicates no trades occurred and provides a market closed status. The content is presented as a financial data point from TradingView, with data provided by ICE Data Services and FactSet.
CRISPR Therapeutics (CRSP) is transitioning into a commercial-stage biotech with the initial success of its gene-editing therapy, Casgevy, which exceeded Q4 2025 sales expectations and shows accelerating patient adoption. Beyond Casgevy, CRSP boasts a robust pipeline including therapies for cardiovascular and autoimmune diseases, leveraging its gene-editing and siRNA platforms for long-term growth. Despite current unprofitability, the company's strong cash reserves and positive analyst sentiment suggest significant upside, positioning CRSP as a high-risk, high-reward investment in the gene-editing revolution.
This article provides an overview of CRISPR Therapeutics AG (NASDAQ: CRSP) stock performance, financial data, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along with other financial metrics like revenue and EBITDA. The content also addresses frequently asked questions about investing in CRSP stock.
The article provides a forecast and price target for CRISPR Therapeutics AG (CRSP) stock, based on analyst opinions. It includes current stock performance metrics, historical price data, upcoming earnings report dates, and various financial figures such as market capitalization, revenue, and net income. The article emphasizes that the information is not investment advice and encourages readers to conduct their own research.
CRISPR Therapeutics presented its strategic shift towards a disease-focused model at the TD Cowen 46th Annual Health Care Conference, emphasizing cardiovascular and autoimmune franchises with expected data from six programs beyond Casgevy by mid-2027. The company detailed strong Casgevy performance with increasing patient initiations and anticipated revenue inflection, alongside updates on its in vivo and cardiovascular pipeline, highlighting promising results for CTX310 and the potential for early intervention with gene editing for conditions like Lp(a).
This article from TradingKey attempts to provide a revenue breakdown for CRISPR Therapeutics AG (CRSP), covering business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant data for these categories has not yet been disclosed by the company. Therefore, no specific financial details or analysis can be provided in this report.
CRISPR Therapeutics (CRSP) recently filed a US$969.16 million ESOP-related shelf registration and amended its articles of association, prompting investors to re-evaluate the company's long-term risk-reward profile. While these moves reinforce equity-based compensation and balance sheet flexibility, the core investment narrative still hinges on clinical, regulatory, and commercialization progress of its gene-editing platforms. The potential for future dilution from the large equity overhang is a key concern, especially given the wide range of fair value estimates from the Simply Wall St Community.
CRISPR Therapeutics (CRSP) recently filed a US$969.16 million ESOP-linked shelf registration and amended its articles of association, moves that reinforce equity-based compensation and balance sheet flexibility. This comes as investors reassess the company's long-term risk-reward profile, focusing on clinical and commercialization progress despite persistent losses and dilution risks. The shelf registration is seen as maintaining the existing investment narrative rather than introducing new catalysts for the gene-editing company.
Analysts have issued neutral ratings for enGene Holdings (ENGN) and Intellia Therapeutics (NTLA), indicating an evenly balanced outlook. Wells Fargo assigned a Hold rating to enGene Holdings with a $2.00 price target, while Bank of America Securities maintained a Hold rating on Intellia Therapeutics with a $19.00 price target. Both companies collectively hold a 'Moderate Buy' analyst consensus, though the individual ratings lean towards caution.
CRISPR Therapeutics AG (CRSP) has seen increased investor attention, with its stock performing well recently, up 8.3% over the past month. Analysts project a loss of $1.13 per share for the current quarter but anticipate a significant revenue increase of 733.3%. While the company has surpassed EPS estimates twice in the last four quarters, its valuation currently indicates it trades at a premium.
Blue Jean Financial LLC initiated a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, purchasing 28,037 shares valued at approximately $1.47 million. Institutional investment in CRISPR Therapeutics remains robust, with hedge funds and other investors holding 69.20% of the company's stock, including significant increases from JPMorgan Chase & Co. and UBS Group AG. Despite reporting a quarterly loss of $1.28 per share and limited revenue, analysts maintain a "Moderate Buy" rating with an average price target of $67.78.
Wall Street Zen has downgraded CRISPR Therapeutics (NASDAQ:CRSP) from "hold" to "sell," despite the broader analyst consensus being a "Moderate Buy." The stock has seen a 0.9% decline, trading below its 50-day and 200-day moving averages, and the company reported a quarterly loss of $1.28 per share, with analysts expecting a full-year loss. Insider activity shows sales by Naimish Patel and CEO Samarth Kulkarni, while institutional investors have made minor adjustments to their holdings.
Analysts have provided new ratings for healthcare companies Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE). Morgan Stanley upgraded Crispr Therapeutics to Hold with a $60.00 price target, while William Blair reiterated a Buy rating on Hinge Health. Both companies have an analyst consensus of Moderate Buy and Strong Buy respectively, indicating potential upsides for investors.
Crispr Therapeutics stock gained 3% in pre-open trading after Morgan Stanley initiated coverage with an "Equalweight" rating and a $60 price target, predicting significant Casgevy sales and profitability by 2029. Mizuho Securities also issued a "Buy" rating, adding to existing positive analyst sentiment. This positive news from analysts provided a company-specific catalyst despite a broader market decline.
Morgan Stanley initiated coverage on CRISPR Therapeutics (NASDAQ:CRSP) with an equalweight rating and a price target of $60.00, noting that the near-term upside from its gene-editing therapy, Casgevy, is largely reflected in the current valuation. The firm projects significant sales growth for Casgevy, reaching an estimated $3 billion by 2035, and expects further key data releases in 2026. Other analysts have adjusted their price targets and ratings, reflecting varied perspectives but general optimism about the company's gene-editing prospects and robust balance sheet.
CRISPR Therapeutics AG's average 12-month price target has been lowered slightly to $81.1 from $82.15, based on estimates from 21 analysts. This updated target indicates a potential upside of approximately 64% from the June 10 closing price. Despite the small cut in the price target, the consensus rating from 26 analysts remains a "Buy."
CRISPR Therapeutics AG (CRSP) experienced a 3.9% drop in its latest trading session, underperforming the broader market indices like the S&P 500, Dow, and Nasdaq. The company's stock has also seen a decline over the past month, contrasting with gains in the Medical sector. Investors are looking forward to its upcoming earnings report, with projections of significant year-over-year growth in both earnings per share and revenue.
Norges Bank has acquired a new stake of 490,206 shares in CRISPR Therapeutics AG (NASDAQ:CRSP), valued at approximately $25.7 million, representing about 0.51% of the company. Other institutional investors also increased their holdings, with institutional ownership now at 69.2%. Despite the increased institutional interest, CRISPR Therapeutics shares remained largely unchanged at $51.48, and the company continues to report losses, with analysts expecting a full-year EPS of -$4.92.
Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.5% in the fourth quarter, selling 205,564 shares. Despite this, CRISPR Therapeutics remains a significant holding for Amova, accounting for 1.2% of its portfolio. Other institutional investors like Orbis Allan Gray Ltd and SR One Capital Management LP increased their positions in the company, while the stock currently trades at $51.48 with a market cap of $4.97 billion.
CRISPR Therapeutics AG director Douglas A. Treco received a stock option grant of 13,000 common shares with an exercise price of $51.84 per share. This grant, awarded at no purchase cost, vests in 12 equal monthly installments starting June 30, 2026, and expires on June 5, 2036. The transaction is categorized as a compensation-related acquisition rather than an open-market purchase or sale.
Christian Rommel, a director at CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options with an exercise price of $51.84 per share, expiring on June 5, 2036. This compensation-related award is not an open-market transaction and will vest in 12 equal monthly installments, beginning June 30, 2026, subject to his continued service. The grant is detailed in a Form 4 SEC filing, outlining the vesting schedule and terms for these derivative securities.
CRISPR Therapeutics AG director John Greene was granted stock options for 13,000 common shares. These options have an exercise price of $51.84 and expire on June 5, 2036. The award vests in 12 equal monthly installments, with the first installment vesting on June 30, 2026.
This article reports an insider trading activity for CRISPR Therapeutics AG (CRSP) as detailed in a Form 4 SEC filing. Director Morrison Briggs acquired 13,000 stock options (right to buy) at an exercise price of $51.84, with vesting occurring in monthly installments over one year. The filing summary indicates a neutral impact and sentiment regarding this transaction.
Contrarius Group Holdings Ltd reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 42.1% in the fourth quarter, selling 113,745 shares and ending up with 156,605 shares valued at approximately $8.21 million. Other institutional investors adjusted their positions, and hedge funds now own 69.2% of the company's stock. Insider selling has also been noted, while analysts currently maintain a "Moderate Buy" rating with an average price target of $65.47.
Capital International Investors raised its stake in CRISPR Therapeutics AG by 4.3% in the fourth quarter, acquiring an additional 243,487 shares, bringing its total holding to 5.89 million shares valued at approximately $309 million. Other institutional investors also increased their positions, with hedge funds and institutions collectively owning 69.2% of the stock. Despite reporting a quarterly loss of $1.28 per share, analysts maintain a "Moderate Buy" rating with a consensus price target of $65.47, reflecting continued interest from major investors.
CRISPR Therapeutics' stock has stagnated despite its gene-editing therapy Casgevy receiving approval and treating over 500 patients. Concerns remain regarding the therapy's high cost, complex treatment process, and the potential for dilution from recent convertible notes. Wall Street analysts predict a significant price increase, but profitability challenges are hindering investor confidence.
CRISPR Therapeutics (CRSP) shares dropped 7.7% after the company filed a shelf registration for nearly US$1 billion in common shares tied to employee stock plans and updated its articles of association. These moves aim to provide financial and governance flexibility as the company commercializes Casgevy and advances its cardiovascular gene-editing pipeline. The article highlights that while the company's long-term potential in gene-editing is compelling, investors face risks from significant shareholder dilution and the company's current unprofitability.
CRISPR Therapeutics (CRSP) is regaining investor interest due to the commercial launch of Casgevy and progress in its gene editing pipeline. While currently unprofitable on a reported net income basis, analysts forecast profitability, and the stock is trading below some price targets. A discounted cash flow model suggests the stock is significantly undervalued, but risks remain due to ongoing losses and the time it will take for the broader gene editing portfolio to generate substantial revenue.
Geode Capital Management LLC has increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.0% in the fourth quarter, bringing its total holdings to 2.25 million shares valued at approximately $118 million. Despite a recent 9.0% drop in share price to $51.84 and reported quarterly losses, analyst sentiment for CRSP remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $65.47. Several other institutional investors also adjusted their positions in CRSP, and company insiders have recently sold shares.
Healthcare sector analysts have issued bullish sentiments on Insulet (PODD) and Crispr Therapeutics AG (CRSP). William Blair maintained a Buy rating on Insulet with a consensus price target of $233.72, signaling a 61.8% upside. Similarly, Crispr Therapeutics AG also received a Buy rating from William Blair, with a price target consensus of $75.00.
